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Studies have demonstrated that local angiotensin II (AngII) generation is
enhanced in repairing kidney and angiotensin converting enzyme (ACE)
inhibition or AT1 receptor blockade attenuates renal fibrosis. The local-
ization of ACE and AngII receptors and their relationship to collagen
synthesis in the injured kidney, however, remains uncertain. Using a rat
model of renal injury with subsequent fibrosis created by chronic eleva-
tions in circulating aldosterone (ALDO), we examined the distribution
and binding density of ACE and AngII receptors in repairing kidneys, as
well as their anatomic relationship to transforming growth factor (TGF)-
beta 1 mRNA, type I collagen mRNA, collagen accumulation and myo-
fibroblasts (myoFb). Two groups of animals (n57/group) were studied:
1) normal rats served as controls; and 2) uninephrectomized rats received
ALDO (0.75mg/hr sc) and 1% NaCl in drinking water for 6 weeks.
Compared to controls, in ALDO-treated rats we found: 1) significantly
(P,0.01) increased blood pressure and reduced plasma renin activity and
increased plasma creatinine; 2) diffuse fibrosis in both renal cortex and
medulla; 3) abundant myoFb at these sites of fibrosis, 4) significantly
increased (P,0.01) binding density of ACE and AngII receptors (60%
AT1: 40% AT2) at sites of fibrosis; and 5) markedly increased (P,0.01)
expression of TGF-beta 1 and type I collagen mRNAs at these same sites.
Thus, in this rat model of renal repair, enhanced expression of ACE,
AngII receptors and TGF-beta 1 are associated with renal fibrosis. AngII
generated at sites of repair appears to have autocrine/paracrine functions
in regulating renal fibrous tissue formation alone or through its stimula-
tion of TGF-beta 1 synthesis.
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Introduction: The goal of gene therapy for hypertension is to produce
safe, prolonged reductions of high blood pressure with a single admin-
istration of a transgene. We have develeloped gene therapy using adeno-
associated virus (AAV) antisense (AS) as a vector because it is safe,
stable and effective. To test systemic injection in an adult hypertensive
model, this study uses double transgenic (dt) mice, with human renin
(hR) and human transgenes. In these mice, plasma Ang II levels are
elevated and blood pressure increased (~140-160 mmHg), compared to
controls (~100 mmHg). Methods: Therefore, dt mice with established
baseline BP of .140-160 mmHg (n55) were systemically injected (100
ml) with a single dose of 4x1010 infectious particles of rAAV-AT1R-AS.
The rAAV contained a CMV promoter and neo1 reporter gene. Control
(n55) received the rAAV vector without AS. Blood pressure recordings
by the tailcuff method were made once per week for up to 6 months.
Results: One week after injection, BP decreased by 35-50 mmHg
(p,0.001, compared to baseline). The normalized blood pressure per-
sisted for the full length of the study. Individual mice were sacrificed at
14-28 weeks and tissues taken for detection of rAAV-AT1-R-AS. At both
time periods, the AS-AT1R transgene was present in lung, kidney, liver,
heart, adrenal gland and fat. The rAAV was not detected in the brain.
Renal arterioles (n56) showed a reduction (50%) contractile response to
increasing log doses of Ang II, compared to controls (n56) (p,0.01).
Autoradiography of AT1-R showed a reduction in receptors in the rAAT-
AT1R-AS treated group only. Conclusion: The results demonstrated that
a single systemic delivery of rAAV-AT1R-AS in adult, hypertensive
mice produces a profound decrease in blood pressure for at least 6
months. The prolonged effect is due to the continuous expression of the
AT1R AS transgene inhibiting AT1 receptors. The results encourage
further development of the rAAV with engineering to make AS transgene
expression tissue-specific and switchable on or off for safety.
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Excessive circulating angiotensin II (Ang II) and reduced nitric oxide
(NO) are independently associated with end organ damage. However,
low dose infusions of Ang II that only increase plasma Ang II levels
2-fold, cause no detectable end organ damage (Hu et al J Hyper 16: 1285,
1998). To determine possible interactions between the two systems, we
coinfused low dose Ang II and L-NAME in chronically catheterized
Sprague-Dawley rats.
After 5 days saline infusion, L-NAME (10 mg/kg/min) was infused for
20 days. After 6 days of L-NAME, Ang II (10ng/kg/min) was coinfused
for 14 days (LA, 16 rats). Two other groups of rats were infused with
L-NAME (L, 8 rats), or saline (C, 5 rats) alone.
Blood pressure and heart rate were monitored continuously. Plasma
renin (PRC) was measured daily. Plasma cardiac troponin T (cTnT) and
urinary albumin (UA) were measured as indices of cardiac and renal
damage, respectively. At the end of the study, hearts and kidneys were
assessed histologically.
cTnT rose and then fell sharply 1 to 4 days after the start of Ang II, and
then remained elevated. cTnT was always undetectable in L or C rats. UA
began to rise after 4-5 days Ang II infusion and continued to rise
thereafter. L-NAME done did not increase UA. Unlike L rats, LA rats
had extensive cardiac and renal perivascular fibrosis, glomerular damage,
and an increase in the overall cardiac collagen volume. Renal parenchy-
mal damage was increased in both LA and L rats, but was much greater
in the LA group.
Taken together, these observations show that there is greatly increased
renal and cardiac damage when Ang II and L-NAME are infused together
over two weeks at doses that, when infused alone, produce relatively little
injury. Thus, Ang II may cause greater end organ damage in a setting of
reduced NO bioavailability.
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In vitro studies have shown that telmisartan is an insurmountable angio-
tensin II AT-1 receptor antagonist. In this study we have investigated the
molecular basis of this insurmountable antagonism. The association and
dissociation kinetics of telmisartan to angiotensin AT-1 receptors were
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measured using an in vitro radio-receptor binding assay. These
radioligand binding studies were conducted either directly on rat
vascular (aorta) smooth muscle cells (RVSMC) expressing solely the
AT-1 receptor or on membrane preparation obtained from the same
cells.
The specific binding of 3H-telmisartan to the surface of living RVSMC
or membranes was saturable. From these data, a Kd value of 1.7 nM was
estimated. Scatchard analysis of the 3H-telmisartan binding on RVSMC
indicated the existence of a single class of binding sites. The affinity of
telmisartan for AT-1 receptor is only poorly affected by the presence of
proteins (0.4% of rat plasma proteins) in the binding buffer, indicating
that no great competition between telmisartan binding to its specific AT-1
receptor and to non-specific proteins binding sites occurs. In association
experiments, the specific binding of 3H-telmisartan increases quickly and
reaches equilibrium within less than 1 hour, with an association rate
constant calculated to be 0.006 min-1nM-1. Telmisartan dissociates very
slowly from the AT-1 receptor, either in RVSMC membrane preparation
or in living cells with a dissociation rate constant of ca. 0.01 min-1
resulting in a dissociation half-life (t1/2) of about 60 min, which is
comparable to the previously published data for candesartan in bovine
adrenal cortical membranes and almost 5 times slower than that of
125I-angiotensin II binding (t1/2512 min). In contrast to candesartan that
has been shown to re-associate with the AT-1 receptor, telmisartan does
not appear to re-associate. Indeed, when the dissociation of labeled-
telmisartan from AT-1 receptors was induced by washing the cells with
cold-binding buffer, followed by addition of fresh binding buffer con-
taining either cold telmisartan, Ang II or losartan, or nothing, no differ-
ence were observed in the dissociation rate constants measured with
telmisartan whatever the composition of the binding buffer after removal
of labeled-telmisartan.
In conclusion, these results suggest that the insurmountable antago-
nism of telmisartan is due mainly to its very slow dissociation from
angiotensin AT-1 receptors.
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